

# Mary Jeanne Kreek

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1707157/publications.pdf>

Version: 2024-02-01

179  
papers

9,874  
citations

44069

48  
h-index

39675

94  
g-index

182  
all docs

182  
docs citations

182  
times ranked

7783  
citing authors

#	ARTICLE	IF	CITATIONS
1	Analyses of polymorphisms of intron 2 of OPRK1 (kappa-opioid receptor gene) in association with opioid and cocaine dependence diagnoses in an African-American population. <i>Neuroscience Letters</i> , 2022, 768, 136364.	2.1	7
2	Sex and chronic stress alter the distribution of glutamate receptors within rat hippocampal CA3 pyramidal cells following oxycodone conditioned place preference. <i>Neurobiology of Stress</i> , 2022, 17, 100431.	4.0	2
3	Characterization of Pyrrolidinyl-hexahydro-pyranopiperazines as a Novel Kappa Opioid Receptor Agonist Scaffold. <i>ACS Chemical Neuroscience</i> , 2022, 13, 1849-1856.	3.5	2
4	Population-specific genetic background for the OPRM1 variant rs1799971 (118A>G): implications for genomic medicine and functional analysis. <i>Molecular Psychiatry</i> , 2021, 26, 3169-3177.	7.9	11
5	The Laboratory of the Biology of Addictive Diseases: Four Women in Neuroscience. <i>Journal of Neuroscience Research</i> , 2021, 99, 29-36.	2.9	1
6	Oxycodone injections not paired with conditioned place preference have little effect on the hippocampal opioid system in female and male rats. <i>Synapse</i> , 2021, 75, e22182.	1.2	3
7	Blockade of alcohol excessive and "relapse" drinking in male mice by pharmacological cryptochrome (CRY) activation. <i>Psychopharmacology</i> , 2021, 238, 1099-1109.	3.1	2
8	Association of Serotonin Transporter (SERT) Polymorphisms with Opioid Dependence and Dimensional Aspects of Cocaine Use in a Caucasian Cohort of Opioid Users. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 659-670.	2.2	5
9	Chronic stress differentially alters mRNA expression of opioid peptides and receptors in the dorsal hippocampus of female and male rats. <i>Journal of Comparative Neurology</i> , 2021, 529, 2636-2657.	1.6	11
10	Profile of a short-acting $\mu$ -antagonist, LY2795050, on self-grooming behaviors, forced swim test and locomotor activity: sex comparison in mice. <i>Journal of Psychopharmacology</i> , 2021, 35, 579-590.	4.0	5
11	OPRD1 SNPs associated with opioid addiction are cis-eQTLs for the phosphatase and actin regulator 4 gene, PHACTR4, a mediator of cytoskeletal dynamics. <i>Translational Psychiatry</i> , 2021, 11, 316.	4.8	7
12	Nalmefene, a mu opioid receptor antagonist/kappa opioid receptor partial agonist, potentiates cocaine motivation but not intake with extended access self-administration in adult male mice. <i>Neuropharmacology</i> , 2021, 192, 108590.	4.1	3
13	Acute Delta 9-tetrahydrocannabinol administration differentially alters the hippocampal opioid system in adult female and male rats. <i>Synapse</i> , 2021, 75, e22218.	1.2	2
14	Age of onset of heaviest use of cannabis or alcohol in persons with severe opioid or cocaine use disorders. <i>Drug and Alcohol Dependence</i> , 2021, 226, 108834.	3.2	2
15	Design, synthesis, and preliminary evaluation of a potential synthetic opioid rescue agent. <i>Journal of Biomedical Science</i> , 2021, 28, 62.	7.0	8
16	Preclinical Studies on Nalfurafine (TRK-820), a Clinically Used KOR Agonist. <i>Handbook of Experimental Pharmacology</i> , 2021, 271, 137-162.	1.8	8
17	Genetic Vulnerability to Opioid Addiction. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021, 11, a039735.	6.2	6
18	Polymorphisms in Stress-Related Genes Are Associated with Reduced Cocaine Abuse and Longer Retention in Methadone Maintenance Treatment for Opioid Use Disorder. <i>European Addiction Research</i> , 2021, 27, 198-205.	2.4	1

#	ARTICLE	IF	CITATIONS
19	Murine model of OPRM1 A118G alters oxycodone self-administration and locomotor activation, but not conditioned place preference. <i>Neuropharmacology</i> , 2020, 167, 107864.	4.1	9
20	Sex and chronic stress alter delta opioid receptor distribution within rat hippocampal CA1 pyramidal cells following behavioral challenges. <i>Neurobiology of Stress</i> , 2020, 13, 100236.	4.0	4
21	Relapse-like behavior in a mouse model of the OPRM1 (mu-opioid receptor) A118G polymorphism: Examination with intravenous oxycodone self-administration. <i>Neuropharmacology</i> , 2020, 181, 108351.	4.1	6
22	Kappa Opioid Receptor Antagonists as Potential Therapeutics for Mood and Substance Use Disorders. <i>Handbook of Experimental Pharmacology</i> , 2020, 271, 473-491.	1.8	11
23	Review of addiction risk potential associated with adolescent opioid use. <i>Pharmacology Biochemistry and Behavior</i> , 2020, 198, 173022.	2.9	12
24	Nalfurafine modulates the reinforcing effects of oxycodone in male and female adolescent C57BL/6J mice. <i>Neuropharmacology</i> , 2020, 176, 108244.	4.1	7
25	Further evidence for the association of <i>GAL</i> , <i>GALR1</i> and <i>NPY1R</i> variants with opioid dependence. <i>Pharmacogenomics</i> , 2020, 21, 903-917.	1.3	1
26	Variants of opioid genes and response to treatment of opioid use disorder with buprenorphine-naloxone versus extended-release naltrexone in Caucasians. <i>American Journal of Drug and Alcohol Abuse</i> , 2020, 46, 761-768.	2.1	3
27	mTORC1 pathway is involved in the kappa opioid receptor activation-induced increase in excessive alcohol drinking in mice. <i>Pharmacology Biochemistry and Behavior</i> , 2020, 195, 172954.	2.9	5
28	Bruce S. McEwen, Ph.D.. <i>Neuropsychopharmacology</i> , 2020, 45, 1079-1079.	5.4	0
29	Neuroendocrine effects of naltrexone versus nalmefene in humans. <i>Human Psychopharmacology</i> , 2020, 35, e2726.	1.5	6
30	Effects of Kappa opioid receptor blockade by LY2444296 HCl, a selective short-acting antagonist, during chronic extended access cocaine self-administration and re-exposure in rat. <i>Psychopharmacology</i> , 2020, 237, 1147-1160.	3.1	15
31	Modulation of cocaine-related behaviors by low doses of the potent KOR agonist nalfurafine in male C57BL6 mice. <i>Psychopharmacology</i> , 2020, 237, 2405-2418.	3.1	12
32	Current status of opioid addiction treatment and related preclinical research. <i>Science Advances</i> , 2019, 5, eaax9140.	10.3	60
33	Clinically utilized kappa-opioid receptor agonist nalfurafine combined with low-dose naltrexone prevents alcohol relapse-like drinking in male and female mice. <i>Brain Research</i> , 2019, 1724, 146410.	2.2	9
34	Sex and chronic stress differentially alter phosphorylated mu and delta opioid receptor levels in the rat hippocampus following oxycodone conditioned place preference. <i>Neuroscience Letters</i> , 2019, 713, 134514.	2.1	12
35	Kappa Opioid Receptors and Mu Opioid Receptors as Combined Targets for Medication Development for Alcoholism. <i>Biological Psychiatry</i> , 2019, 86, 809-810.	1.3	2
36	A 3' UTR SNP rs885863, a cis-eQTL for the circadian gene <i>VIPR2</i> and lincRNA 689, is associated with opioid addiction. <i>PLoS ONE</i> , 2019, 14, e0224399.	2.5	8

#	ARTICLE	IF	CITATIONS
37	Escalation of drug use in persons dually diagnosed with opioid and cocaine dependence: Gender comparison and dimensional predictors. <i>Drug and Alcohol Dependence</i> , 2019, 205, 107657.	3.2	11
38	Sex Differences in Neuroplasticity- and Stress-Related Gene Expression and Protein Levels in the Rat Hippocampus Following Oxycodone Conditioned Place Preference. <i>Neuroscience</i> , 2019, 410, 274-292.	2.3	20
39	VMAT2 gene ( <i>SLC18A2</i> ) variants associated with a greater risk for developing opioid dependence. <i>Pharmacogenomics</i> , 2019, 20, 331-341.	1.3	8
40	Impact of Pharmacological Manipulation of the $\mu$ -Opioid Receptor System on Self-grooming and Anhedonic-like Behaviors in Male Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 370, 1-8.	2.5	27
41	Combination of Clinically Utilized Kappa Opioid Receptor Agonist Nalfurafine With Low Dose Naltrexone Reduces Excessive Alcohol Drinking in Male and Female Mice. <i>Alcoholism: Clinical and Experimental Research</i> , 2019, 43, 1077-1090.	2.4	18
42	Association of variants of prodynorphin promoter 68-bp repeats in caucasians with opioid dependence diagnosis: Effect on age trajectory of heroin use. <i>Neuroscience Letters</i> , 2019, 704, 100-105.	2.1	5
43	Chronic immobilization stress primes the hippocampal opioid system for oxycodone-associated learning in female but not male rats. <i>Synapse</i> , 2019, 73, e22088.	1.2	11
44	Genetic variations in genes of the stress response pathway are associated with prolonged abstinence from heroin. <i>Pharmacogenomics</i> , 2018, 19, 333-341.	1.3	12
45	Effects of mesyl salvinorin B alone and in combination with naltrexone on alcohol deprivation effect in male and female mice. <i>Neuroscience Letters</i> , 2018, 673, 19-23.	2.1	12
46	Involvement of Activated Brain Stress Responsive Systems in Excessive and Relapse Alcohol Drinking in Rodent Models: Implications for Therapeutics. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 366, 9-20.	2.5	18
47	Structurally Related Kappa Opioid Receptor Agonists with Substantial Differential Signaling Bias: Neuroendocrine and Behavioral Effects in C57BL6 Mice. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 847-857.	2.1	32
48	Sex differences after chronic stress in the expression of opioid-, stress- and neuroplasticity-related genes in the rat hippocampus. <i>Neurobiology of Stress</i> , 2018, 8, 33-41.	4.0	32
49	Dopamine gene variants in opioid addiction: comparison of dependent patients, nondependent users and healthy controls. <i>Pharmacogenomics</i> , 2018, 19, 95-104.	1.3	15
50	Repeated Administration of Opra Kappa (LY2456302), a Novel, Short-Acting, Selective KOP-r Antagonist, in Persons with and without Cocaine Dependence. <i>Neuropsychopharmacology</i> , 2018, 43, 739-750.	5.4	50
51	V1b Receptor Antagonist <i>SSR149415</i> and Naltrexone Synergistically Decrease Excessive Alcohol Drinking in Male and Female Mice. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 195-205.	2.4	17
52	Gender-specific association of functional $\mu$ -prodynorphin 68 bp repeats with cannabis exposure in an African American cohort. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 1025-1034.	2.2	9
53	Sex Differences in the Rat Hippocampal Opioid System After Oxycodone Conditioned Place Preference. <i>Neuroscience</i> , 2018, 393, 236-257.	2.3	24
54	A non-coding CRHR2 SNP rs255105, a cis-eQTL for a downstream lincRNA AC005154.6, is associated with heroin addiction. <i>PLoS ONE</i> , 2018, 13, e0199951.	2.5	11

#	ARTICLE	IF	CITATIONS
55	Chronic Oxycodone Self-administration Altered Reward-related Genes in the Ventral and Dorsal Striatum of C57BL/6J Mice: An RNA-seq Analysis. <i>Neuroscience</i> , 2018, 393, 333-349.	2.3	39
56	Non-medical Cannabis Self-Exposure as a Dimensional Predictor of Opioid Dependence Diagnosis: A Propensity Score Matched Analysis. <i>Frontiers in Psychiatry</i> , 2018, 9, 283.	2.6	14
57	Oprm1 A112G, a single nucleotide polymorphism, alters expression of stress-responsive genes in multiple brain regions in male and female mice. <i>Psychopharmacology</i> , 2018, 235, 2703-2711.	3.1	7
58	Re-evaluation of the KMSK scales, rapid dimensional measures of self-exposure to specific drugs: Gender-specific features. <i>Drug and Alcohol Dependence</i> , 2018, 190, 179-187.	3.2	15
59	Naltrexone and nalmefene attenuate cocaine place preference in male mice. <i>Neuropharmacology</i> , 2018, 140, 174-183.	4.1	9
60	Endogenous opioid system in addiction and addiction-related behaviors. <i>Current Opinion in Behavioral Sciences</i> , 2017, 13, 196-202.	3.9	10
61	Effects of the novel relatively short-acting kappa opioid receptor antagonist LY2444296 in behaviors observed after chronic extended-access cocaine self-administration in rats. <i>Psychopharmacology</i> , 2017, 234, 2219-2231.	3.1	41
62	Synergistic blockade of alcohol escalation drinking in mice by a combination of novel kappa opioid receptor agonist Mesyl Salvinorin B and naltrexone. <i>Brain Research</i> , 2017, 1662, 75-86.	2.2	20
63	Association of Variants of Arginine Vasopressin and Arginine Vasopressin Receptor 1A With Severe Acetaminophen Liver Injury. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2017, 3, 500-505.	4.5	10
64	Hypothalamic-specific proopiomelanocortin deficiency reduces alcohol drinking in male and female mice. <i>Genes, Brain and Behavior</i> , 2017, 16, 449-461.	2.2	20
65	The $\mu$ -opioid receptor nonsynonymous variant 118A>G is associated with prolonged abstinence from heroin without agonist treatment. <i>Pharmacogenomics</i> , 2017, 18, 1387-1391.	1.3	17
66	Medications for substance use disorders (SUD): emerging approaches. <i>Expert Opinion on Emerging Drugs</i> , 2017, 22, 301-315.	2.4	13
67	Blockade of alcohol escalation and relapse drinking by pharmacological FAAH inhibition in male and female C57BL/6J mice. <i>Psychopharmacology</i> , 2017, 234, 2955-2970.	3.1	43
68	Alterations of expression of inflammation/immune-related genes in the dorsal and ventral striatum of adult C57BL/6J mice following chronic oxycodone self-administration: a RNA sequencing study. <i>Psychopharmacology</i> , 2017, 234, 2259-2275.	3.1	54
69	Can a rapid measure of self-exposure to drugs of abuse provide dimensional information on depression comorbidity?. <i>American Journal on Addictions</i> , 2017, 26, 632-639.	1.4	4
70	Involvement of Endocannabinoids in Alcohol Binge Drinking: Studies of Mice with Human Fatty Acid Amide Hydrolase Genetic Variation and After CB1 Receptor Antagonists. <i>Alcoholism: Clinical and Experimental Research</i> , 2016, 40, 467-473.	2.4	36
71	Sex differences in responsiveness to the prescription opioid oxycodone in mice. <i>Pharmacology Biochemistry and Behavior</i> , 2016, 148, 99-105.	2.9	50
72	Discriminative Stimulus Properties of Opioid Ligands: Progress and Future Directions. <i>Current Topics in Behavioral Neurosciences</i> , 2016, 39, 175-192.	1.7	4

#	ARTICLE	IF	CITATIONS
73	Variants of opioid system genes are associated with non-dependent opioid use and heroin dependence. <i>Drug and Alcohol Dependence</i> , 2016, 168, 164-169.	3.2	14
74	Adolescent oxycodone self administration alters subsequent oxycodone-induced conditioned place preference and anti-nociceptive effect in C57BL/6J mice in adulthood. <i>Neuropharmacology</i> , 2016, 111, 314-322.	4.1	27
75	African-specific variability in the acetylcholine muscarinic receptor M4: association with cocaine and heroin addiction. <i>Pharmacogenomics</i> , 2016, 17, 995-1003.	1.3	12
76	Strain and cocaine-induced differential opioid gene expression may predispose Lewis but not Fischer rats to escalate cocaine self-administration. <i>Neuropharmacology</i> , 2016, 105, 639-650.	4.1	29
77	Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts. <i>Behavior Genetics</i> , 2016, 46, 151-169.	2.1	98
78	Glutamatergic and GABAergic susceptibility loci for heroin and cocaine addiction in subjects of African and European ancestry. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 64, 118-123.	4.8	17
79	Synaptic Plasticity and Signal Transduction Gene Polymorphisms and Vulnerability to Drug Addictions in Populations of European or African Ancestry. <i>CNS Neuroscience and Therapeutics</i> , 2015, 21, 898-904.	3.9	21
80	Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders. <i>Frontiers in Pharmacology</i> , 2015, 6, 190.	3.5	47
81	Persistent increases in rat hypothalamic POMC gene expression following chronic withdrawal from chronic "binge" pattern escalating-dose, but not steady-dose, cocaine. <i>Neuroscience</i> , 2015, 289, 63-70.	2.3	10
82	Susceptibility loci for heroin and cocaine addiction in the serotonergic and adrenergic pathways in populations of different ancestry. <i>Pharmacogenomics</i> , 2015, 16, 1329-1342.	1.3	15
83	Self administration of oxycodone alters synaptic plasticity gene expression in the hippocampus differentially in male adolescent and adult mice. <i>Neuroscience</i> , 2015, 285, 34-46.	2.3	39
84	Individual differences in gene expression of vasopressin, D2 receptor, POMC and orexin: Vulnerability to relapse to heroin-seeking in rats. <i>Physiology and Behavior</i> , 2015, 139, 127-135.	2.1	30
85	Mouse Model of the OPRM1 (A118G) Polymorphism: Differential Heroin Self-Administration Behavior Compared with Wild-Type Mice. <i>Neuropsychopharmacology</i> , 2015, 40, 1091-1100.	5.4	49
86	Effects of handling and vehicle injections on adrenocorticotrophic and corticosterone concentrations in Sprague-Dawley compared with Lewis rats. <i>Journal of the American Association for Laboratory Animal Science</i> , 2015, 54, 35-9.	1.2	29
87	Self administration of oxycodone by adolescent and adult mice affects striatal neurotransmitter receptor gene expression. <i>Neuroscience</i> , 2014, 258, 280-291.	2.3	26
88	Alcohol: A stimulant activating brain stress responsive systems with persistent neuroadaptation. <i>Neuropharmacology</i> , 2014, 87, 51-58.	4.1	31
89	Personality as a risk factor for illicit opioid use and a protective factor for illicit opioid dependence. <i>Drug and Alcohol Dependence</i> , 2014, 145, 101-105.	3.2	29
90	Extended access oxycodone self-administration and neurotransmitter receptor gene expression in the dorsal striatum of adult C57BL/6J mice. <i>Psychopharmacology</i> , 2014, 231, 1277-1287.	3.1	53

#	ARTICLE	IF	CITATIONS
91	Stress-related genes and heroin addiction: A role for a functional FKBP5 haplotype. <i>Psychoneuroendocrinology</i> , 2014, 45, 67-76.	2.7	62
92	Mu-opioid receptor A118G polymorphism in healthy volunteers affects hypothalamic-pituitary-adrenal axis adrenocorticotrophic hormone stress response to metyrapone. <i>Addiction Biology</i> , 2013, 18, 325-331.	2.6	34
93	CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. <i>Addiction Biology</i> , 2013, 18, 709-716.	2.6	88
94	Regional mRNA expression of GABAergic receptor subunits in brains of C57BL/6J and 129P3/J mice: Strain and heroin effects. <i>Brain Research</i> , 2013, 1523, 49-58.	2.2	6
95	Kappa Opioids: Problems and Opportunities in Analgesia. <i>ACS Symposium Series</i> , 2013, , 245-256.	0.5	2
96	Methadone Maintenance Treatment Experience in Macao - Prospective Follow-up for Initial 4.5 Years. <i>Journal of Psychoactive Drugs</i> , 2013, 45, 313-321.	1.7	3
97	Addictions and Stress: Clues for Cocaine Pharmacotherapies. <i>Current Pharmaceutical Design</i> , 2013, 19, 7065-7080.	1.9	19
98	Nerve growth factor $\beta$ 2 polypeptide (NGFB) genetic variability: association with the methadone dose required for effective maintenance treatment. <i>Pharmacogenomics Journal</i> , 2012, 12, 319-327.	2.0	23
99	$\delta$ -opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction. <i>Trends in Neurosciences</i> , 2012, 35, 587-596.	8.6	165
100	Dose escalation and dose preference in extended-access heroin self-administration in Lewis and Fischer rats. <i>Psychopharmacology</i> , 2012, 220, 163-172.	3.1	43
101	Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics. <i>Journal of Clinical Investigation</i> , 2012, 122, 3387-3393.	8.2	178
102	Functions of Arginine Vasopressin and Its Receptors: Importance of Human Molecular Genetics Studies in Bidirectional Translational Research. <i>Biological Psychiatry</i> , 2011, 70, 502-503.	1.3	8
103	Cell-specific effects of variants of the 68-base pair tandem repeat on <i>prodynorphin</i> gene promoter activity. <i>Addiction Biology</i> , 2011, 16, 334-346.	2.6	27
104	Extreme marginalization: addiction and other mental health disorders, stigma, and imprisonment. <i>Annals of the New York Academy of Sciences</i> , 2011, 1231, 65-72.	3.8	39
105	Haplotype block structure of the genomic region of the mu opioid receptor gene. <i>Journal of Human Genetics</i> , 2011, 56, 147-155.	2.3	31
106	Evidence for association of two variants of the nociceptin/orphanin FQ receptor gene <i>OPRL1</i> with vulnerability to develop opiate addiction in Caucasians. <i>Psychiatric Genetics</i> , 2010, 20, 65-72.	1.1	19
107	Genome-wide association study identifies genes that may contribute to risk for developing heroin addiction. <i>Psychiatric Genetics</i> , 2010, 20, 207-214.	1.1	58
108	Ethnic diversity of DNA methylation in the <i>OPRM1</i> promoter region in lymphocytes of heroin addicts. <i>Human Genetics</i> , 2010, 127, 639-649.	3.8	76

#	ARTICLE	IF	CITATIONS
109	Drug-induced and genetic alterations in stress-responsive systems: Implications for specific addictive diseases. <i>Brain Research</i> , 2010, 1314, 235-252.	2.2	51
110	Association of polymorphisms of the cannabinoid receptor (CNR1) and fatty acid amide hydrolase (FAAH) genes with heroin addiction: impact of long repeats of CNR1. <i>Pharmacogenomics Journal</i> , 2010, 10, 232-242.	2.0	44
111	Pharmacotherapy in the Treatment of Addiction: Methadone. <i>Journal of Addictive Diseases</i> , 2010, 29, 200-216.	1.3	91
112	Overview and historical perspective of four papers presented on research related to the endogenous opioid system. <i>Drug and Alcohol Dependence</i> , 2010, 108, 195-199.	3.2	6
113	Acute withdrawal from chronic escalating-dose binge cocaine administration alters kappa opioid receptor stimulation of [ S ] guanosine 5'€²-O-[gamma-thio]triphosphate acid binding in the rat ventral tegmental area. <i>Neuroscience</i> , 2010, 169, 751-757.	2.3	17
114	Neuropathic and chronic pain stimuli downregulate central 1/4 -opioid and dopaminergic transmission. <i>Trends in Pharmacological Sciences</i> , 2010, 31, 299-305.	8.7	96
115	Opiate and cocaine addiction: from bench to clinic and back to the bench. <i>Current Opinion in Pharmacology</i> , 2009, 9, 74-80.	3.5	65
116	Bidirectional translational research: Progress in understanding addictive diseases. <i>Neuropharmacology</i> , 2009, 56, 32-43.	4.1	26
117	Treating chronic hepatitis C in recovering opiate addicts: yes, we can. <i>Digestive and Liver Disease</i> , 2009, 41, 308-310.	0.9	4
118	Catecholâ€œmethyltransferase (COMT) gene variants: Possible association of the Val158Met variant with opiate addiction in hispanic women. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008, 147B, 793-798.	1.7	31
119	Genetic susceptibility to heroin addiction: a candidate gene association study. <i>Genes, Brain and Behavior</i> , 2008, 7, 720-729.	2.2	189
120	Role of a Functional Human Gene Polymorphism in Stress Responsivity and Addictions. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 615-618.	4.7	23
121	Markers for hepatitis A, B and C in methadone maintained patients: an unexpectedly high co-infection with silent hepatitis B. <i>Addiction</i> , 2008, 103, 681-686.	3.3	14
122	One-Year and Cumulative Retention as Predictors of Success in Methadone Maintenance Treatment: A Comparison of Two Clinics in the United States and Israel. <i>Journal of Addictive Diseases</i> , 2008, 27, 11-25.	1.3	116
123	ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. <i>Human Molecular Genetics</i> , 2008, 17, 2219-2227.	2.9	150
124	Prodynorphin gene promoter repeat associated with cocaine/alcohol codependence. <i>Addiction Biology</i> , 2007, 12, 496-502.	2.6	45
125	Stress Responsivity, Addiction, and a Functional Variant of the Human Mu-Opioid Receptor Gene. <i>Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics</i> , 2007, 7, 74-78.	3.4	45
126	Opioids, dopamine, stress, and the addictions. <i>Dialogues in Clinical Neuroscience</i> , 2007, 9, 363-378.	3.7	13

#	ARTICLE	IF	CITATIONS
127	Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. <i>Nature Neuroscience</i> , 2005, 8, 1450-1457.	14.8	925
128	Increased Attributable Risk Related to a Functional $\mu$ -Opioid Receptor Gene Polymorphism in Association with Alcohol Dependence in Central Sweden. <i>Neuropsychopharmacology</i> , 2005, 30, 417-422.	5.4	198
129	Pharmacogenetics and Human Molecular Genetics of Opiate and Cocaine Addictions and Their Treatments. <i>Pharmacological Reviews</i> , 2005, 57, 1-26.	16.0	338
130	Nalmefene Induced Elevation in Serum Prolactin in Normal Human Volunteers: Partial Kappa Opioid Agonist Activity?. <i>Neuropsychopharmacology</i> , 2005, 30, 2254-2262.	5.4	121
131	Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden. <i>Molecular Psychiatry</i> , 2004, 9, 547-549.	7.9	155
132	Genes Associated With Addiction: Alcoholism, Opiate, and Cocaine Addiction. <i>NeuroMolecular Medicine</i> , 2004, 5, 085-108.	3.4	109
133	Evolving perspectives on neurobiological research on the addictions: celebration of the 30th anniversary of NIDA. <i>Neuropharmacology</i> , 2004, 47, 324-344.	4.1	97
134	1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. <i>Lancet, The</i> , 2003, 361, 662-668.	13.7	416
135	History and current status of opioid maintenance treatments: blending conference session. <i>Journal of Substance Abuse Treatment</i> , 2002, 23, 93-105.	2.8	110
136	Pharmacotherapy of addictions. <i>Nature Reviews Drug Discovery</i> , 2002, 1, 710-726.	46.4	326
137	Novel and previously reported single nucleotide polymorphisms in the human $\mu$ receptor gene: No association with cocaine or alcohol abuse or dependence. <i>American Journal of Medical Genetics Part A</i> , 2001, 105, 489-497.	2.4	54
138	Altered HPA Axis Responsivity to Metyrapone Testing in Methadone Maintained Former Heroin Addicts with Ongoing Cocaine Addiction. <i>Neuropsychopharmacology</i> , 2001, 24, 568-575.	5.4	74
139	Detection of single nucleotide polymorphisms of the human mu opioid receptor gene by hybridization or single nucleotide extension on custom oligonucleotide gelpad microchips: Potential in studies of addiction. <i>American Journal of Medical Genetics Part A</i> , 2000, 96, 604-615.	2.4	56
140	Lethal methadone intoxications in Geneva, Switzerland, from 1994 to 1998. <i>Addiction</i> , 2000, 95, 1647-1653.	3.3	46
141	Reduced Hypothalamic POMC and Anterior Pituitary CRF1 Receptor mRNA Levels After Acute, but Not Chronic, Daily "Binge" Intra-gastric Alcohol Administration. <i>Alcoholism: Clinical and Experimental Research</i> , 2000, 24, 1575-1582.	2.4	40
142	Methadone-Related Opioid Agonist Pharmacotherapy for Heroin Addiction: History, Recent Molecular and Neurochemical Research and Future in Mainstream Medicine. <i>Annals of the New York Academy of Sciences</i> , 2000, 909, 186-216.	3.8	215
143	Replication of an Effective Opiate Addiction Pharmacotherapeutic Treatment Model. <i>Journal of Maintenance in the Addictions</i> , 2000, 1, 5-13.	0.1	26
144	Opioid receptor imaging with positron emission tomography and [(18)F]cyclofoxy in long-term, methadone-treated former heroin addicts. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2000, 295, 1070-6.	2.5	86

#	ARTICLE	IF	CITATIONS
145	Cocaine Abuse Sharply Reduced in an Effective Methadone Maintenance Program. <i>Journal of Addictive Diseases</i> , 1999, 18, 63-75.	1.3	61
146	Variable Dose Naltrexone-Induced Hypothalamic-Pituitary-Adrenal Stimulation in Abstinent Alcoholics: A Preliminary Study. <i>Alcoholism: Clinical and Experimental Research</i> , 1999, 23, 502-508.	2.4	34
147	Acute intermittent morphine increases preprodynorphin and kappa opioid receptor mRNA levels in the rat brain. <i>Molecular Brain Research</i> , 1999, 66, 184-187.	2.3	51
148	Dynorphin A(1-13) Analgesia in Opioid-Treated Patients with Chronic Pain. <i>Clinical Drug Investigation</i> , 1999, 17, 33-42.	2.2	10
149	Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1999, 288, 260-9.	2.5	67
150	Nalmefene Causes Greater Hypothalamic-Pituitary-Adrenal Axis Activation than Naloxone in Normal Volunteers: Implications for the Treatment of Alcoholism. <i>Alcoholism: Clinical and Experimental Research</i> , 1998, 22, 1430-1436.	2.4	93
151	Sustained Withdrawal Allows Normalization of In Vivo [ <sup>11</sup> C]N-Methylspiperone Dopamine D2 Receptor Binding after Chronic Binge Cocaine A Positron Emission Tomography Study in Rats. <i>Neuropsychopharmacology</i> , 1998, 19, 146-153.	5.4	49
152	Selective regulation of dopamine transporter binding in the shell of the nucleus accumbens by adrenalectomy and corticosterone-replacement. , 1998, 30, 334-337.		31
153	Effects of dynorphin A(1-13) on opiate withdrawal in humans. <i>Psychopharmacology</i> , 1998, 137, 326-332.	3.1	34
154	Single-nucleotide polymorphism in the human mu opioid receptor gene alters $\mu$ -endorphin binding and activity: Possible implications for opiate addiction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 9608-9613.	7.1	1,075
155	Naltrexone Biotransformation and Incidence of Subjective Side Effects: A Preliminary Study. <i>Alcoholism: Clinical and Experimental Research</i> , 1997, 21, 906-909.	2.4	58
156	Quantitation of dopamine transporter mRNA in the rat brain: Mapping, effects of 'binge' cocaine administration and withdrawal. , 1997, 26, 55-61.		34
157	Opioid receptors: Some perspectives from early studies of their role in normal physiology, stress responsivity, and in specific addictive diseases. <i>Neurochemical Research</i> , 1996, 21, 1469-1488.	3.3	82
158	Simplified quantitation of urinary benzoyllecgonine in cocaine addiction research and for related pharmacotherapeutic trials. <i>Addiction</i> , 1996, 91, 1687-1697.	3.3	4
159	Cocaine, Dopamine and the Endogenous Opioid System. <i>Journal of Addictive Diseases</i> , 1996, 15, 73-96.	1.3	91
160	Effect of clonidine pretreatment on naloxone-precipitated opiate withdrawal. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1996, 276, 1128-35.	2.5	27
161	Opiates, opioids and addiction. <i>Molecular Psychiatry</i> , 1996, 1, 232-54.	7.9	91
162	Effects of Ethanol on Human Natural Killer Cell Activity: In Vitro and Acute, Low-Dose In Vivo Studies. <i>Alcoholism: Clinical and Experimental Research</i> , 1994, 18, 1361-1367.	2.4	29

#	ARTICLE	IF	CITATIONS
163	Effects of morphine on prolactin receptors in the rat brain. <i>FEBS Letters</i> , 1994, 338, 207-211.	2.8	6
164	Biological correlates of methadone maintenance pharmacotherapy. <i>Annales De Médecine Interne</i> , 1994, 145 Suppl 3, 9-14.	0.2	1
165	Treatment of opioid-induced constipation with oral naloxone: A pilot study. <i>Clinical Pharmacology and Therapeutics</i> , 1992, 52, 90-95.	4.7	240
166	Immune function in heroin addicts and former heroin addicts in treatment: pre- and post-AIDS epidemic. <i>NIDA Research Monograph</i> , 1990, 96, 192-219.	0.1	6
167	HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987. <i>JAMA - Journal of the American Medical Association</i> , 1989, 261, 1008-1012.	7.4	209
168	Specificity of Antibody Tests for Human Immunodeficiency Virus in Alcohol and Parenteral Drug Abusers with Chronic Liver Disease. <i>Alcoholism: Clinical and Experimental Research</i> , 1988, 12, 687-690.	2.4	15
169	Effect of Severe Alcoholic Liver Disease on the Disposition of Methadone in Maintenance Patients. <i>Alcoholism: Clinical and Experimental Research</i> , 1985, 9, 349-354.	2.4	48
170	ACTH, cortisol and $\beta$ -endorphin response to metyrapone testing during chronic methadone maintenance treatment in humans. <i>Neuropeptides</i> , 1984, 5, 277-278.	2.2	94
171	Circadian rhythms and levels of $\beta$ -endorphin, acth, and cortisol during chronic methadone maintenance treatment in humans. <i>Life Sciences</i> , 1983, 33, 409-411.	4.3	83
172	Quantitation of Methadone Eeantiomers in Humans Using Stable Isotope-labeled [2H3]-, [2H5]-, and [2H8]methadone. <i>Journal of Pharmaceutical Sciences</i> , 1982, 71, 40-43.	3.3	43
173	Acute effects of ethanol on hepatic uptake and distribution of narcotics in the isolated perfused rabbit liver. <i>Hepatology</i> , 1981, 1, 419-423.	7.3	3
174	Methadone disposition in patients with chronic liver disease. <i>Clinical Pharmacology and Therapeutics</i> , 1981, 30, 353-362.	4.7	91
175	Stereoselective disposition of methadone in man. <i>Life Sciences</i> , 1979, 24, 925-932.	4.3	60
176	Quantitative Analysis of Methadone in Biological Fluids Using Deuterium-Labeled Methadone and GLC-Chemical-Ionization Mass Spectrometry. <i>Journal of Pharmaceutical Sciences</i> , 1977, 66, 1579-1582.	3.3	30
177	Methadone-maintained patients. Effect of methadone on plasma testosterone, FSH, LH, and prolactin. <i>New York State Journal of Medicine</i> , 1974, 74, 1970-3.	0.1	10
178	Plasma and urine levels of methadone. Comparison following four medication forms used in chronic maintenance treatment. <i>New York State Journal of Medicine</i> , 1973, 73, 2773-7.	0.1	38
179	Narcotic blockade. <i>Archives of Internal Medicine</i> , 1966, 118, 304-9.	3.8	92